Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accumulated Expenses (2016 - 2025)

United Therapeutics' Accumulated Expenses history spans 17 years, with the latest figure at $480.9 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 42.07% to $480.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $480.9 million, a 42.07% increase, with the full-year FY2025 number at $480.9 million, up 42.07% from a year prior.
  • Accumulated Expenses hit $480.9 million in Q4 2025 for United Therapeutics, up from $338.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for UTHR hit a ceiling of $480.9 million in Q4 2025 and a floor of $170.8 million in Q4 2021.
  • Historically, Accumulated Expenses has averaged $301.7 million across 5 years, with a median of $292.4 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: decreased 6.62% in 2021 and later skyrocketed 42.07% in 2025.
  • Tracing UTHR's Accumulated Expenses over 5 years: stood at $170.8 million in 2021, then surged by 32.2% to $225.8 million in 2022, then rose by 29.5% to $292.4 million in 2023, then grew by 15.77% to $338.5 million in 2024, then skyrocketed by 42.07% to $480.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for UTHR at $480.9 million in Q4 2025, $338.5 million in Q4 2024, and $292.4 million in Q4 2023.